ArticleJNCI cancer spectrum2026
Engaging community oncology stakeholders to plan multisite cancer caregiving research (CONNECT WF-2300CD).
Article in JNCI cancer spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundEngaging community stakeholders in clinical trials planning identifies participation barriers and facilitators to support future trial success. We assessed interest and perceived capacity of the National Cancer Institute Community Oncology Research Program (NCORP) practices and engaged stakeholders to inform a future multisite clinical trial involving caregivers.
methodsA cross-sectional survey of NCORP practices (WF-2300CD) assessed interest (somewhat or very likely to participate) and capacity (ie, criteria: ≥5 eligible dyad accruals per quarter, identification of necessary study implementers) and barriers and facilitators to participating in a future cancer caregiver-focused trial. Interest and capacity were estimated with 95% confidence intervals (CIs), and logistic regression was used to identify statistically significant predictors. Free-text responses were analyzed using content analysis.
resultsAmong 136 initial responding practices, 126 (92%) completed the survey (November 2023-April 2024), 56% saw at least 1000 new patient cases annually, 13.5% served at least 30% racial and ethnic minority patients, and 13.5% were designated critical access hospitals. Overall, 84.9% (95% CI = 77.5% to 90.1%) expressed interest in a caregiver-focused trial, but only 37.3% (95% CI = 28.9% to 46.4%) met all capacity criteria; capacity was the sole predictor of interest (adjusted odds ratio [OR] = 5.79, 95% CI = 1.23 to 27.13). Most (88.9%) practices estimated 5 or more eligible caregiver-patient dyads per quarter, but only 44.4% believed they could accrue that amount. Key participation barriers included staffing limitations and challenges related to eligibility and recruitment. Practices emphasized clear guidance on dyad eligibility, recruitment materials, workflow training, and resource considerations to improve trial participation.
conclusionEarly stakeholder engagement identified actionable barriers and produced practice-aligned strategies to enhance caregiver trial participation in community oncology settings. Targeted capacity building may improve participation for future caregiver-focused trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.